Font Size: 

 

Abnormalities of glucose metabolism that occur in diabetic patients describe an increased risk in the development and prognosis of certain cancers. Metformin is a first-line therapy for patients with type 2 diabetes melitus has been associated with a reduced risk of various cancer cells.This study compares and analyzes the effectiveness of treatment in group of metformin or combination and non-metformin towards anti-p53 antibody ​​and their relation to HbA1c in T2DM patients who have risk factors for cancer. Type of research is an observational study using cross-sectional method with a total sample is 32 people in Puskesmas Pasar Minggu, Puskesmas Cimanggis, RSUD Depok, and volunteers patient in Tangerang district using total sampling technique.Anti-p53 antibody was measured using elisa kit MESACUP anti-p53 Test whereas HbA1c was  measured in accredited clinical lab by ion exchange HPLC method. The average of anti-p53 antibody is 0,17 ± 0,07  in metformin single dose/combinations group and 0,25 ± 0,12 in non-metformin group. Moreover, there was no significance difference between the group of metformin or combination and non-metformin (p = 0,970). On the other hand, there was a strongly negative correlation between HbA1c values and anti-p53 antibody ​​in group of non-metformin (r = -0,709; p = 0,003) but none in the metformin single dose or combinations group (r = -0,056; p = 0,830).